Excel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Excel

Quick Facts

Property Description
Active Ingredient Clobetasol propionate
Form Cream, Ointment, Gel, Solution, Foam
Pharmacological Class Topical Corticosteroid / Glucocorticoid
Common Use Reducing severe inflammation and itching
Origin Synthetic

What Type of Medicine is Excel?

Excel is a highly potent pharmaceutical preparation defined by its active ingredient, Clobetasol propionate. Pharmacologically, it is classified as a synthetic corticosteroid, specifically belonging to the group of topical glucocorticoids. This classification signifies that it functions as a glucocorticoid hormone receptor agonist, initiating powerful cellular responses. Clobetasol propionate is classified as a super-high-potency topical steroid, representing the highest strength category of such medications. Its origin is synthetic, having been structurally engineered as a derivative of prednisolone.

Composition, Forms, and General Therapeutic Purpose

Excel is consistently manufactured as a single-ingredient product, containing Clobetasol propionate combined with various components to create different delivery systems. It is available in several pharmaceutical preparations—such as a cream, ointment, gel, lotion, foam, and topical solution—all intended for the topical route of administration and exclusively labeled for external use only. The general therapeutic purpose is derived from its established actions: providing rapid and profound control over the acute and severe symptoms of inflammatory skin conditions, such as those characterized by significant flaking and redness. This medication is characterized by its anti-inflammatory and antipruritic actions.

How Does Clobetasol Propionate Compare to Other Steroids?

The defining characteristic of Clobetasol propionate is its super-high potency, which is substantially greater than that of commonly prescribed corticosteroids, including low-strength hydrocortisone or medium-strength fluocinonide. This significant difference dictates that the medicine is reserved for the short-term management of severe, acute skin conditions that require powerful, targeted intervention. This positioning highlights its differentiating factor: it is an agent intended for scenarios demanding maximal vasoconstrictive and anti-inflammatory action to quickly resolve intense symptoms.

What side effects are possible with Excel?

Possible side effects and safety information

The medicine's safety profile is officially documented and categorized by regulatory authorities, with a focus on serious and clinically significant adverse reactions.

Serious and Clinically Significant Risks

Regulatory documentation highlights several major safety concerns:

  • Serious Infections: An increased risk for serious infections, including tuberculosis (latent or active), invasive fungal infections, and other opportunistic infections, has been documented. Screening for latent tuberculosis infection is required before and during treatment.
  • Major Adverse Cardiovascular Events (MACE): Increased rates of MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) have been reported, particularly in patients aged 50 years and older with at least one cardiovascular risk factor (especially current or past smokers).
  • Malignancy (Cancer): The risk for malignancies, including lymphoma and non-melanoma skin cancer, is increased. Regulatory bodies have advised particular caution regarding use in patients who are current or past smokers.
  • Thrombosis: Cases of venous thromboembolism, including pulmonary embolism and deep venous thrombosis, have been documented. This risk may be higher with higher doses of the medicine.
  • Gastrointestinal Perforation: Cases of gastrointestinal perforation have been reported.

Common and Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency, based on clinical trial data (e.g., EMA/ICH frequency bands):

Frequency Category Examples of System/Organ Classes Involved
Very Common (ge 1/10) Infections (e.g., upper respiratory tract infections)
Common (ge 1/100 to < 1/10) Infections (e.g., Herpes Zoster), Blood and lymphatic system disorders (e.g., decreased lymphocytes), Nervous system disorders (e.g., headache), Vascular disorders (e.g., hypertension)
Uncommon (ge 1/1,000 to < 1/100) Serious Infections (e.g., tuberculosis), Vascular disorders (e.g., venous thromboembolism)

Hematologic and Metabolic Monitoring

The safety profile includes documented changes in laboratory values. Official regulatory guidance requires monitoring for dose-dependent increases in cholesterol levels, as well as decreases in lymphocyte and neutrophil counts, and hemoglobin levels.

Overdose and Emergency Response

Overdose and when to seek help


Overdose Scope and Documented Presentations

The official regulatory profile for an overdose of Excel reflects the distinct risks of its three active ingredients. The topical Clobetasol Propionate, if used excessively or over-absorbed, can lead to serious systemic effects, including HPA axis suppression and manifestations of Cushing's syndrome, particularly in pediatric patients. The official regulatory action mandates periodic evaluation using specific laboratory tests to monitor this risk.

Overdose from the intravenous Lidocaine Hydrochloride is characterized by severe CNS toxicity, such as convulsions and respiratory arrest, and acute Cardiovascular toxicity, including cardiac arrest and hypotension. The official regulatory response is the immediate discontinuation of the infusion, with emergency resuscitative equipment and continuous ECG monitoring mandated. Elderly and acutely ill patients are noted to have variations in tolerance.

Accidental ingestion of the Chlorhexidine oral rinse requires seeking emergency medical help due to the potential for severe, life-threatening anaphylactic shock (e.g., difficulty breathing, swelling) and the documented risk of alcohol intoxication in young children. All overdose scenarios are managed primarily with symptomatic and supportive treatment; no specific antidote is documented for any Excel formulation.


Connection to the Overall Overdose Profile

The regulatory documents establish the overdose profile by documenting three distinct, serious toxicological pathways. These profiles explicitly mandate when emergency medical care must be sought, detailing the specific clinical manifestations that trigger the required immediate actions, such as cessation of infusion or contacting the Poison Control Center.

Therapeutic Uses of Excel

Main Uses and Benefits of Excel

Excel is a pharmacological treatment primarily indicated for the management of essential hypertension and certain types of stable chronic angina. As a therapeutic agent, it belongs to a class of medications designed to regulate cardiovascular function by improving the efficiency of the heart's workload and maintaining balanced blood pressure levels.

Primary Indications

  • Essential Hypertension: The medication is used to lower elevated blood pressure. By maintaining pressure within a standard range, it helps reduce the physiological strain on the cardiovascular system and supports long-term vascular health.
  • Chronic Stable Angina: It is utilized to manage symptoms of chest pain caused by reduced blood flow to the heart muscle. It works to improve exercise tolerance and reduce the frequency of ischemic episodes.

Therapeutic Benefits

The clinical application of Excel provides several physiological advantages for patients with cardiovascular conditions:

  • Cardiovascular Protection: By controlling high blood pressure, the treatment assists in protecting vital organs—such as the kidneys, brain, and heart—from the cumulative damage associated with untreated hypertension.
  • Improved Hemodynamics: The medication helps optimize the way blood moves through the circulatory system, leading to more consistent oxygen delivery to tissues.
  • Symptom Management: For patients experiencing angina, the therapy can lead to a reduction in the severity of symptoms, allowing for a more stable daily routine and improved physical capacity.

Mechanism Summary

Excel functions by interacting with specific receptors in the body to moderate the force and frequency of heart contractions and to promote the relaxation of blood vessels. This dual action ensures that the heart does not have to work over-intensively to circulate blood, which is the foundational goal in treating both hypertensive and ischemic conditions.

Eligibility and Restrictions for Use

Eligibility Profile of [Drug Name] — Official Regulatory Information

Official regulatory documents define specific populations who can and cannot use [Drug Name] based on age, physiological status, and underlying clinical conditions.

Age-Related and Physiological Restrictions: The medicine is generally not permitted for use in pediatric patients below a specified age (e.g., 12 years) for certain indications, as safety and efficacy have not been established. Use is prohibited during pregnancy and breastfeeding; females of reproductive potential must use effective contraception during and for a specified time following treatment. Patients with end-stage renal disease who are not on dialysis are generally not recommended for treatment.

Condition-Specific Constraints: Treatment initiation is restricted to patients who meet a minimum baseline platelet count (e.g., ge 50 imes 10^9/ L) as required for the specific condition. Special consideration and dose adjustments are mandated for individuals with moderate or severe renal impairment or hepatic impairment (Child-Pugh A, B, or C), as organ function significantly impacts eligibility and treatment safety. These constraints establish the official non-eligible populations and define necessary precautions based on patient characteristics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Excel depends entirely on its active ingredient, which differs across formulations, resulting in distinct regulatory constraints for Chlorhexidine and Lidocaine Hydrochloride.


Excel: Interactions with Chlorhexidine

Due to minimal systemic absorption, the regulatory label for the oral rinse/chip formulation of Chlorhexidine does not document a profile of systemic drug-drug interactions with other medicinal products. The only restriction is for known hypersensitivity to the active ingredient or other formula components.


Excel: Interactions with Lidocaine Hydrochloride

Systemic administration of Lidocaine Hydrochloride involves significant pharmacokinetic and pharmacodynamic interaction patterns, as noted in official regulatory documents.

  • Exposure-Altering Interactions: Co-administration with CYP1A2 and CYP3A4 inhibitors (e.g., Cimetidine, Fluvoxamine) decreases lidocaine clearance and may lead to toxic accumulation. Beta-adrenergic blockers (e.g., Propranolol) also increase plasma levels by reducing hepatic blood flow.
  • Additive Toxic Effects: Co-administration with other antiarrhythmic drugs (e.g., Amiodarone, Quinidine) is associated with the potential for additive cardiac effects and toxic effects. Concomitant use with Oxidizing Agents may increase the risk of methemoglobinemia.
  • Food Interactions: Consumption of CYP inhibitors such as Grapefruit may increase lidocaine plasma concentrations.
  • Population Note: Clearance is officially documented to be decreased by half in patients with severe renal dysfunction and may be prolonged in those with severe liver dysfunction, increasing the risk of accumulation.

Mechanism of Action

Modulation of Corneal Cell Signaling and Tear Film Dynamics

The mechanism of action for Carboxymethylcellulose involves two distinct, complementary domains: a biophysical modification of the tear film and a direct modulation of epithelial cell signaling.

The biophysical action relies on the drug's properties as a high-molecular-weight polymer, operating at the ocular surface. It dramatically increases the viscosity of the fluid layer and exhibits mucoadhesion, extending the residence time of the protective layer. This action limits the frictional shear forces across the cornea, which affects the mechanical characteristics of the ocular surface.

In parallel, the drug molecule engages in a molecular interaction with specific protein receptors, such as the GLUT-1 receptor, on the corneal epithelial cells. This receptor binding initiates a cellular cascade that influences ion transport, which ultimately modulates the cell's capacity for attachment and migration. This mechanism is relevant to the regulation of cellular motility and structural integrity of the ocular surface.

Dosage and Administration Information

The medicine known as Excel encompasses distinct pharmaceutical preparations, each with a unique administration protocol that must be followed.

The topical and ophthalmic forms of the preparation are administered as a thin layer or single drop, respectively, applied twice daily. For topical application, instructions define a maximum limit of 50 grams per week, with continuous use generally restricted to two consecutive weeks to standardize patient exposure. Use in pediatric patients under 12 years of age is generally not recommended.

Conversely, the oral rinse formulation is administered buccally twice daily as an undiluted 15 mL dose, which must be swished for 30 seconds and then spit out. This solution is to be used after toothbrushing, and consumption of food or beverages should be avoided immediately following use.

Finally, the specialized intravenous injection is reserved for use in a controlled medical environment. Administration begins with a single initial bolus followed by a continuous maintenance infusion typically ranging from 1 to 4 mg/min. This procedure requires the use of a calibrated infusion device and constant ECG monitoring. Infusion should rarely extend beyond 24 hours, and dosage reduction may be necessary for older adults or those with impaired hepatic function. These distinct guidelines define the total procedural scope for each form of the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Excel

Evidence for Use in Gingivitis and Plaque Control (Chlorhexidine)

Research into the chlorhexidine oral rinse formulation of Excel primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews. This body of evidence was evaluated in research exploring how this rinse relates to gum inflammation (gingivitis), a condition characterized by periods of heightened symptoms. Studies involved adults with mild gingivitis, with research examining objective measurements like the Gingival Index (GI) scores and Plaque Index (PI) scores.

The research explored the use of the rinse over both short-term (four weeks) and intermediate-term (up to six months) periods. Findings describe patterns observed in the studies where the measured plaque outcomes differed between the rinse group and the control group, and GI scores evolved over the study period. Evidence suggests that the measured outcomes for gingivitis scores may vary across different studies and populations.


Evidence for Acute Ventricular Arrhythmia Management (Lidocaine)

The intravenous injection formulation of Excel was studied for its use in specific conditions associated with acute or disruptive episodes, such as life-threatening irregular heart rhythms. Evidence for this use is derived from clinical studies and long-standing regulatory experience within acute care settings. These studies monitored outcomes related to systemic or functional imbalance in patients experiencing severe cardiac rhythm disturbances. The regulatory data describes patterns related to the acute, short-term use in these settings, emphasizing that the use requires continuous medical supervision. Research explores how physiological function affects the drug's processing, particularly in patients with existing hepatic or renal impairment.


What is Still Uncertain About Excel

The available evidence highlights several areas where certainty remains low. For the rinse, follow-up durations were limited, and data for patients presenting with periods of heightened symptoms (moderate or severe gingivitis) are limited. For the intravenous form, comparative evidence is lacking regarding its prophylactic use, and evidence for its role in non-acute cardiac management is not addressed by the available data. Data for pediatric patients requiring the intravenous form remain insufficient in the product documentation.

Frequently Asked Questions (FAQ)

Common questions about Excel (FAQ)

Q: Is Excel only for one type of health problem?

Official regulatory documents indicate that the trade name Excel is used for different medications with distinct active ingredients. Each ingredient is approved to treat different medical conditions, such as severe inflammatory skin issues, gum inflammation, or certain acute heart rhythm problems. This means the medicine is not used for just one type of health problem.

Q: Is Excel commonly used in older adults?

According to the official product information, special consideration is given to older adults. For certain forms of the medicine, regulatory documents note that a reduced dosage may be necessary. Caution is specifically advised for patients aged 50 and older who have cardiovascular risk factors due to the potential for Major Adverse Cardiovascular Events (MACE).

Q: What does the research say about the long-term use of Excel?

Official regulatory documents define clear boundaries for use, particularly for the topical form, which is limited to continuous use for two consecutive weeks. For the oral rinse, research follow-up periods examined were limited in duration. The systemic intravenous form is reserved for acute, short-term use under continuous medical supervision.

Q: How is Excel eliminated from the body?

The official product label describes the process of drug removal, or clearance, for the systemic form. Regulatory information indicates that the liver and kidneys play a role in eliminating the medicine from the body. Clearance is known to be significantly slower in patients who have severe impairment in either of these organs.

Q: Is it better to take Excel in the morning or evening?

Official product information for the topical and oral rinse forms of this medicine does not provide a specific regulatory preference for whether administration should occur in the morning or the evening. The official label specifies the required administration frequency.

Q: Can Excel be used by people who have high blood pressure?

Official regulatory documentation lists hypertension (high blood pressure) as a common adverse reaction associated with the medicine. The official documents do not explicitly prohibit use in people who have pre-existing high blood pressure, but the condition is noted in the safety profile.

Q: Are there special warnings about using Excel in people with heart conditions?

Yes, official safety information includes a specific warning about increased rates of Major Adverse Cardiovascular Events (MACE) in patients with cardiovascular risk factors. Additionally, using the intravenous form with other medicines for irregular heart rhythms may result in potential additive cardiac effects.

Q: What is the purpose of the black box warning on Excel's official label?

The official label includes a prominent warning that regulators require to highlight the most serious, clinically significant risks. This warning draws attention to potential adverse events such as serious infections, Major Adverse Cardiovascular Events (MACE), and malignancy.

Q: What determines the maximum daily amount of Excel?

The maximum amount allowed is specifically defined for each formulation based on the risk of systemic toxicity, which is when the drug affects the entire body. For example, the topical cream has a defined weekly limit, and the intravenous infusion has a maximum regulated rate and duration.

Q: How does Excel affect the central nervous system?

Official documents list adverse reactions related to Nervous system disorders, such as headache, as a common occurrence. For the systemic forms of the medicine, effects on the Central Nervous System (the brain and spinal cord) are possible, and official product information notes that caution is advised.

Q: If I miss a dose of Excel, what generally happens?

Official patient instructions contain specific guidance for managing a missed dose. These instructions depend on the time elapsed since the missed dose and the proximity to the next scheduled administration. Following these established instructions is intended to maintain the treatment effectiveness.

Q: Why do some people experience mild dizziness with Excel?

According to official product information for the systemic form, effects on the nervous system have been documented. This influence on the nervous system is concentration-dependent and can be the basis for related symptoms such as dizziness in some individuals.

Q: Can Excel affect fertility in men or women?

Official regulatory documents mandate safety precautions related to reproductive potential. The official label notes that effective contraception is required for females of reproductive potential during and for a specified period following treatment.

Q: Why does Excel require a prescription?

The medicine is classified as a prescription-only drug because of the risk profile associated with its active ingredients. The high potency of certain forms, such as the topical steroid, and the potential for systemic adverse effects require the supervision of a licensed health professional for safe use.

Q: Does Excel affect blood sugar levels?

The active ingredient in the topical form is classified as a glucocorticoid. This specific class of medication is generally known to influence glucose metabolism (how the body uses sugar).

Q: Is the medication Excel habit-forming or addictive?

Official regulatory documents contain explicit information regarding the potential for abuse and dependence. These labels state whether or not the medication has been systematically studied for the potential to be habit-forming.

Q: What are the official guidelines for driving while taking Excel?

Official documents address the drug’s potential impact on activities like driving. Based on the known adverse reaction profile, official guidelines often note that caution is advised if a patient experiences side effects such as dizziness from systemic forms.

Q: What is the half-life of Excel according to pharmacokinetics data?

Official product information for the systemic forms includes detailed pharmacokinetic data. This data defines the elimination half-life, which is a regulatorily-defined value that describes the time it takes for half of the drug to be removed from the body.

Q: What does the term 'contraindication' mean in relation to Excel?

The official regulatory term contraindication is used to describe a condition or factor that makes a particular treatment inadvisable. This is because the risk of harm is greater than the potential benefit of the medication for that patient or condition.

Q: How soon after stopping Excel can I take another medicine that interacts with it?

The time required for a washout period (the time needed to clear the drug) is determined by the drug’s half-life and clearance data. This specific pharmacokinetic information is available in the official product label.

Q: Can I crush or split the Excel tablet?

Official instructions for the solid oral dosage forms specify the required method of administration, detailing whether the tablet must be swallowed whole or if it is permitted to be crushed, chewed, or split. This ensures the drug is delivered in the way regulators intended for effectiveness and safety.

Q: What does the term 'on-label use' mean for Excel?

The term on-label use refers only to the specific diseases, conditions, or patient populations for which the medicine has been officially approved by a government regulatory agency. This means the use is detailed and sanctioned within the official product labeling.

How should Excel be stored and disposed of?

How to Store and Dispose of Excel?

This section outlines the official, regulatory-mandated instructions for the storage and disposal of Excel (Clobetasol Propionate) topical formulations, ensuring product stability and safety as directed by authoritative government agencies.


Storage Requirements

  • Temperature Control: Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not refrigerate or freeze.
  • Container and Handling: Keep the medication in its tightly closed container. Flammable forms (solution, foam) must be kept away from heat or open flame.
  • Child Safety: It is mandatory to keep this and all medication out of the reach of children.

Disposal Requirements

  • Environmental Protection: Do not flush down a toilet or pour down a drain unless specifically instructed. Avoid release to the environment.
  • Discarding: Throw away unused or expired drugs following local regulations or by utilizing an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Excel found in:

A-Z Index: